Genedrive Plc

As of December 31, 2025, Genedrive Plc carries a market capitalization of 900.90M, placing it among publicly traded companies globally. Its enterprise value stands at 912.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genedrive Plc's next confirmed earnings release is scheduled for November 24, 2026.

As of December 31, 2025, Genedrive Plc has 1.04B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genedrive Plc maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Genedrive Plc's stock has gained approximately 121.95% over the past 52 weeks. The 50-day moving average sits at 1.23, while the 200-day moving average is 1.12.

As of December 31, 2025, Genedrive Plc holds 38.70M in cash and equivalents against 50.00M in total debt, resulting in a net debt position of -38.70M. Total book value stands at -41.50M, with working capital of -2.40M providing operational flexibility.

Genedrive Plc's most recent stock split took place on February 19, 2026 with a 685:693 split ratio.